A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~16 mi. (Rimini, Italy, +383 more cities)

Ospedale degli Infermi

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~18 mi. (Meldola, Italy, +226 more cities)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 0464)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

~18 mi. (Meldola, Italy, +262 more cities)

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica

ER Positive, +1 more biomarker

Breast Adenocarcinoma

giredestrant, +2 more drugs

hormone therapy, +1 more type

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~18 mi. (Meldola, Italy, +131 more cities)

Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1608)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

~18 mi. (Meldola, Italy, +190 more cities)

Istituto Romagnolo per lo Studio dei Tum.ori "Dino Amadori" (IRST)

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

~18 mi. (Meldola, Italy, +120 more cities)

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Infiltrating Bladder Urothelial Carcinoma

atezolizumab

immunotherapy

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

~18 mi. (Meldola, Italy, +206 more cities)

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

~18 mi. (Meldola, Italy, +154 more cities)

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~18 mi. (Meldola, Italy, +202 more cities)

Site IT39011

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~18 mi. (Meldola, Italy, +206 more cities)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

~18 mi. (Meldola, Italy, +141 more cities)

GSK Investigational Site

Multiple Myeloma

belantamab mafodotin

chemotherapy, +1 more type

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

~18 mi. (Meldola, Italy, +170 more cities)

Novartis Investigative Site

ER Negative, +4 more biomarkers

Breast Carcinoma

alpelisib, +1 more drug

chemotherapy, +1 more type